Joseph Moore
Internal Medicine · Tulsa, OKNPI 1104853142
Payments from drug & device makers
Across 400 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$618
- Boehringer Ingelheim$577
- Takeda Pharmaceuticals U.S.A., Inc.$489
- GSK$454
- AbbVie$447
- plus $3K from 37 others
What the payments were for
- Food & beverage$7,202100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$245
- HMG-CoA reductase inhibitor.$139
- Impella$136
- LOKELMA$114
How this compares
$7,208 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,582 | $455,788 |
| IngrezzaValbenazine Tosylate | 84 | $316,055 |
| TrulicityDulaglutide | 224 | $211,925 |
| Invega SustennaPaliperidone Palmitate | 37 | $129,589 |
| XareltoRivaroxaban | 433 | $118,439 |
| Austedo XrDeutetrabenazine | 23 | $112,316 |
| GemtesaVibegron | 466 | $111,573 |
| OzempicSemaglutide | 79 | $82,256 |
| JardianceEmpagliflozin | 232 | $67,495 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,501 |
| EntrestoSacubitril/Valsartan | 131 | $42,013 |
| JanuviaSitagliptin Phosphate | 145 | $39,723 |
| MounjaroTirzepatide | 34 | $37,619 |
| LinzessLinaclotide | 87 | $36,395 |
| Gabapentin | 1,346 | $31,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $618 | $455,7881,582 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $345 | $249,544258 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $295 | $248,028470 claims |
| Novo NordiskOzempic | $303 | $82,25679 claims |
| Boehringer IngelheimJardiance | $577 | $67,495232 claims |
| NovartisEntresto | $104 | $42,013131 claims |
| MerckJanuvia | $141 | $39,723145 claims |
| AbbVieLinzess | $447 | $36,39587 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $29,724130 claims |
| GSKTrelegy Ellipta | $454 | $20,54731 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $17,43625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $489 | $16,96170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Renae MayerTulsa$766K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$195K
- Lam leTulsa$191K
- Stacy ChronisterTulsa$163K
- Katherine CookTulsa$41K
- Layth Al AttarTulsa$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.